Biotech company Immutep (ASX:IMM) completed patient enrolment in the phase II portion of the AIPAC-003 clinical trial in metastatic breast cancer, according to a Thursday filing with the Australian Securities Exchange.

A total of 65 patients will be randomized to receive 30-milligram or 90-milligram doses of eftilagimod alpha in combination with paclitaxel to determine the optimal biological dose in line with the Food and Drug Administration's Project Optimus initiative, the filing said.

Immutep shares slid 2% in midday trade.